Safety-wise, the fear mongering does not hold up to the evidence
People searching "Ro Mounjaro" usually want to know whether a telehealth program can get them tirzepatide, the molecule inside Mounjaro
usually most pronounced during dose escalation Diarrhea : Affects 12-17% of patients, typically mild to moderate in severity Vomiting : Reported in 6-10% of patients, more common at higher doses Constipation : Occurs in 6-11% of patients Abdominal pain and dyspepsia : Generally transient Decreased appetite : An expected pharmacological effect contributing to weight loss Other documented adverse effects include injection site reactions, hypoglycemia (when used with insulin or sulfonylureas), and less commonly, fatigue
The result: habit work that feels like a game, not a chore, with tools built around GLP-1 care and safety
Building a consistent routine, utilizing reminders, and integrating your injection into existing weekly habits are essential strategies for long-term adherence, regardless of your chosen time
I think that's really interesting